氯法齐明能治疗肺结核吗？效果怎么样？

Multidrug-resistant pulmonary tuberculosis (MDR-PTB) is pulmonary tuberculosis that is resistant to at least isoniazid or rifampin. It has the characteristics of long infection time, poor treatment effect, and low sputum bacterial culture conversion rate. At present, second-line drugs with fewer adverse reactions are mostly used for clinical treatment of MDR-PTB, but the efficacy is not good and the treatment cost is relatively expensive. Therefore, finding effective drugs to treat MDR-PTB is a current research problem. It is a drug commonly used to treat leprosy and can produce a complete sensitivity effect in the clinical treatment of multi-drug-resistant tuberculosis. Clofazimine can treat tuberculosis. Let’s talk about the effects of this drug.

120 MDR-PTB patients were selected for a prospective study and divided into two groups according to the random number table method, with 60 cases in each group. The control group was treated with a combination of five anti-tuberculosis drugs, and the observation group was treated with clofazimine on the basis of the control group. Compare the sputum negative conversion and lesion absorption of the two groups of patients at different time points at 6, 12, 18, and 24 months of treatment, and observe the occurrence of complications during the treatment of the two groups of patients.

Results The smear positive to negative conversion rate and PE positive to negative conversion rate of the patients in the observation group were higher than those of the control group at different time points at 6, 12, 18, and 24 months of treatment, and the difference was statistically significant (P<0.05); the effective rate of lesion absorption in the observation group at different time points at 6, 12, 18, and 24 months of treatment was higher than that of the control group, and the difference was statistically significant (P<0.05); there was no statistically significant difference in the total incidence of complications between the two groups of patients during treatment (P >0.05). It is concluded that the clofazimine-containing combination regimen has significant efficacy in the treatment of MDR-PTB patients without increasing the incidence of complications.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.